Presentation with Addex

Fulcrum Pharma PLC
25 January 2005

For immediate release                                            25 January 2005


                               Fulcrum Pharma plc
                          ('Fulcrum' or 'the Company')

       Fulcrum to present at BioBusiness 2005 with Addex Pharmaceuticals

Fulcrum Pharma plc (AIM: FUL), the drug development and strategic outsourcing
services company, announces today that its CEO, Dr Jon Court, will be
co-presenting with the CEO of Addex Pharmaceuticals, Vincent Mutel, at the
BioBusiness 2005 bio-partnering event on Wednesday 26th January 2005 at 14:30 at
the President Wilson Hotel, Geneva.

The presentation will be entitled 'Networked Drug Development: The New Way
Forward'.

During the presentation Addex and Fulcrum will discuss the benefits of working
together and of using a drug development services company to optimise and manage
customer development services.  Fulcrum discusses the merits of its strategy for
increasing the probability of success through giving faster and more cost
effective delivery of drug development programmes.

In 2003, Fulcrum announced that it had signed a preferred supplier arrangement
with Addex, the Swiss pharmaceutical company focused on central nervous system
disorders, whereby Fulcrum would take an equity stake in Addex and receive fees
for service over a three year period.  In return Fulcrum would provide drug
development services for the Addex portfolio of novel compounds.

Dr Jon Court, CEO of Fulcrum Pharma, said: 'We are extremely pleased with the
success of our development partnership with Addex. Our presence at this
conference not only validates our partnership and investment with Addex but also
our business strategy.

'We were pleased to note the recent collaboration and licence agreement that
Addex signed with Ortho-McNeil Pharmaceutical, a Johnson & Johnson company, in
the area of CNS and look forward to our involvement to support that
collaboration.'


For further information, please contact:

Fulcrum Pharma PLC                                          Tel: [phone]
Jon Court, CEO

Buchanan Communications                                     Tel: [phone]
Mary-Jane Johnson


Notes to Editors:

About Fulcrum Pharma

Fulcrum Pharma plc is an independent, drug development company that is the first
to offer global virtual drug development and strategic outsourcing services to
the pharmaceutical industry.  The Company has expertise in the design, execution
and delivery of drug development programmes and relies on state of the art
information technology and infrastructure in the supply of its services.

Through Fulcrum's services to its clients, the Directors believe that there is
the capacity to deliver products faster and more efficiently to the global
pharmaceutical market. Fulcrum does this by using its skills in the design of
drug programmes that deliver the necessary information for decision-making and
product registration. In so doing, Fulcrum works closely with its clients to
meet their strategic R&D goals.

Fulcrum Pharma is listed on the Alternative Investment Market of the London
Stock Exchange having successfully floated in March 2000.


                      This information is provided by RNS
            The company news service from the London Stock Exchange